An analyst sets an $8 price target for Quantum BioPharma

Quantum BioPharma (QNTM) signed a study start-up agreement with Thermo Fisher Scientific for its Phase 2 Lucid-MS trial for multiple sclerosis, following FDA clearance. The trial will evaluate efficacy, safety, and tolerability. MS affects 2.8 million people globally, with the therapeutic market projected to exceed $38B by 2030, according to the company.

Quantum BioPharma (QNTM) announced that the U.S. District Court for the Southern District of New York consolidated its lawsuit and a class action against CIBC and RBC, alleging stock manipulation. The court appointed Grant & Eisenhofer as lead counsel. The lawsuit claims defendants used 'spoofing' techniques to manipulate Quantum's stock price between 2020 and 2024, harming shareholders.

Quantum BioPharma (QNTM) partnered with Thermo Fisher to conduct a Phase 2 trial for its MS drug Lucid-MS, which targets demyelination. The trial marks a key milestone for QNTM, as it aims to offer an alternative to existing immune-focused MS treatments.

Quantum BioPharma (QNTM) has partnered with Thermo Fisher's clinical research business to initiate a Phase 2 trial for its Lucid-MS treatment, which targets demyelination in a novel neuroprotective approach. Thermo Fisher's expertise in central nervous system studies supports the trial's execution.

Quantum BioPharma (QNTM) partnered with Thermo Fisher Scientific's clinical research unit to begin Phase 2 trials for Lucid-MS, its lead multiple sclerosis treatment. This agreement is a key step in the drug's development process.

Quantum BioPharma (QNTM) partnered with Thermo Fisher to launch a Phase 2 trial for Lucid-MS, a drug candidate for progressive multiple sclerosis. The trial follows FDA clearance and aims to target demyelination, a novel approach in MS treatment. Lucid-MS has shown promise in preclinical and Phase 1 trials, with a favorable safety profile. The MS therapeutics market is projected to exceed $38 billion by 2030, according to Grand View Research.